(Q34856914)

4 August 2017

1 reference

title

A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis (English)

1 reference

4 August 2017

0 references

1 reference

1 reference

1 reference

Paresh Dandona

1

1 reference

PubMed ID

12231076

4 August 2017

Ahmad Aljada

series ordinal

2

1 reference

PubMed ID

12231076

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

American Journal of Cardiology

4 August 2017

1 reference

4 August 2017

90

1 reference

4 August 2017

5A

1 reference

4 August 2017

27G-33G

1 reference

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Obesity, atherosclerosis, and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Pathophysiology and treatment of the dyslipidemia of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Platelet adhesion and aggregation in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Lipid peroxide levels of serum lipoprotein fractions of diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Oxidative damage to DNA in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Plasma concentrations of soluble TNF-alpha receptors in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Plasminogen activator inhibitor in plasma and arteriosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Mechanisms of monocyte recruitment and accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Tissue factor-dependent factor VIIa signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Circulating tissue factor and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Regulation of matrix metalloproteinase expression in tumor invasion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

The AP-1 site and MMP gene regulation: what is all the fuss about?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Associations between change in C-reactive protein and serum lipids during statin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Association between C-reactive protein and features of the metabolic syndrome: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Insulin resistance and its treatment by thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Plasma free fatty acids decrease insulin-stimulated skeletal muscle glucose uptake by suppressing glycolysis in conscious rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Function and activation of NF-kappa B in the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

NF-kappa B: ten years after

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

The NF-kappa B and I kappa B proteins: new discoveries and insights

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Role of NF-kappaB in immune and inflammatory responses in the gut.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Interleukin-10: biology, role in inflammation and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Interleukin-10 and the interleukin-10 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Effect of insulin on human aortic endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Insulin and Cardiovascular Disease: Paris Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Prevention of fat-induced insulin resistance by salicylate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Salicylates as hypoglycemic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Enhanced preservation of acutely ischemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Glucose-insulin-potassium reduces infarct size when administered during reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902556-0

10.1016/S0002-9149(02)02556-0

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12231076